Dana B Hancock1, Joshua L Levy2, Nathan C Gaddis2, Cristie Glasheen3, Nancy L Saccone4, Grier P Page5, Gary K Hulse6, Dieter Wildenauer6, Erin A Kelty6, Sibylle G Schwab7, Louisa Degenhardt8, Nicholas G Martin9, Grant W Montgomery9, John Attia10, Elizabeth G Holliday10, Mark McEvoy11, Rodney J Scott12, Laura J Bierut13, Elliot C Nelson13, Alex H Kral14, Eric O Johnson15. 1. Behavioral Health Epidemiology Program, Behavioral Health and Criminal Justice Division, Research Triangle Institute (RTI) International, St. Louis, Missouri.. Electronic address: dhancock@rti.org. 2. Research Computing Division, RTI International, Research Triangle Park, North Carolina, St. Louis, Missouri. 3. Behavioral Health Epidemiology Program, Behavioral Health and Criminal Justice Division, Research Triangle Institute (RTI) International, St. Louis, Missouri. 4. Department of Genetics, Washington University in St. Louis, St. Louis, Missouri. 5. Center for Public Health Genomics, RTI International, Atlanta, Georgia. 6. School of Psychiatry and Clinical Neurosciences, University of Western Australia, Crawley, Western Australia, Australia. 7. Department of Psychiatry and Psychotherapy, University of Erlangen-Nuremberg, Erlangen, Germany.; Faculty of Science, Medicine, and Health, University of Wollongong, Wollongong, New South Wales. 8. National Drug and Alcohol Research Centre, University of New South Wales, Sydney. 9. Queensland Institute of Medical Research Berghofer Medical Research Institute, Brisbane, Queensland. 10. Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales.; Clinical Research Design, IT and Statistical Support Unit, Hunter Medical Research Institute, Newcastle, New South Wales. 11. Centre for Clinical Epidemiology and Biostatistics, School of Medicine and Public Health, University of Newcastle, Newcastle, New South Wales.; Public Health Research Program, Biomarker Discovery and Information-Based Medicine, Hunter Medical Research Institute, Newcastle, New South Wales. 12. Center for Bioinformatics, Biomarker Discovery and Information-Based Medicine, Hunter Medical Research Institute, Newcastle, New South Wales.; School of Biomedical Sciences and Pharmacy, University of Newcastle, Newcastle, New South Wales.; Division of Genetics, Hunter Area Pathology Service, Newcastle, New South Wales, Australia. 13. Department of Psychiatry, Washington University in St. Louis, St. Louis, Missouri. 14. Urban Health Program, Behavioral Health and Criminal Justice Division, RTI International, San Francisco, California. 15. Fellow Program and Behavioral Health and Criminal Justice Division, RTI International, Research Triangle Park, North Carolina.
Abstract
BACKGROUND: No opioid receptor, mu 1 (OPRM1) gene polymorphisms, including the functional single nucleotide polymorphism (SNP) rs1799971, have been conclusively associated with heroin/other opioid addiction, despite their biological plausibility. We used evidence of polymorphisms altering OPRM1 expression in normal human brain tissue to nominate and then test associations with heroin addiction. METHODS: We tested 103 OPRM1 SNPs for association with OPRM1 messenger RNA expression in prefrontal cortex from 224 European Americans and African Americans of the BrainCloud cohort. We then tested the 16 putative cis-expression quantitative trait loci (cis-eQTL) SNPs for association with heroin addiction in the Urban Health Study and two replication cohorts, totaling 16,729 European Americans, African Americans, and Australians of European ancestry. RESULTS: Four putative cis-eQTL SNPs were significantly associated with heroin addiction in the Urban Health Study (smallest p = 8.9 × 10(-5)): rs9478495, rs3778150, rs9384169, and rs562859. Rs3778150, located in OPRM1 intron 1, was significantly replicated (p = 6.3 × 10(-5)). Meta-analysis across all case-control cohorts resulted in p = 4.3 × 10(-8): the rs3778150-C allele (frequency = 16%-19%) being associated with increased heroin addiction risk. Importantly, the functional SNP allele rs1799971-A was associated with heroin addiction only in the presence of rs3778150-C (p = 1.48 × 10(-6) for rs1799971-A/rs3778150-C and p = .79 for rs1799971-A/rs3778150-T haplotypes). Lastly, replication was observed for six other intron 1 SNPs that had prior suggestive associations with heroin addiction (smallest p = 2.7 × 10(-8) for rs3823010). CONCLUSIONS: Our findings show that common OPRM1 intron 1 SNPs have replicable associations with heroin addiction. The haplotype structure of rs3778150 and nearby SNPs may underlie the inconsistent associations between rs1799971 and heroin addiction.
BACKGROUND:No opioid receptor, mu 1 (OPRM1) gene polymorphisms, including the functional single nucleotide polymorphism (SNP) rs1799971, have been conclusively associated with heroin/other opioid addiction, despite their biological plausibility. We used evidence of polymorphisms altering OPRM1 expression in normal human brain tissue to nominate and then test associations with heroin addiction. METHODS: We tested 103 OPRM1 SNPs for association with OPRM1 messenger RNA expression in prefrontal cortex from 224 European Americans and African Americans of the BrainCloud cohort. We then tested the 16 putative cis-expression quantitative trait loci (cis-eQTL) SNPs for association with heroin addiction in the Urban Health Study and two replication cohorts, totaling 16,729 European Americans, African Americans, and Australians of European ancestry. RESULTS: Four putative cis-eQTL SNPs were significantly associated with heroin addiction in the Urban Health Study (smallest p = 8.9 × 10(-5)): rs9478495, rs3778150, rs9384169, and rs562859. Rs3778150, located in OPRM1 intron 1, was significantly replicated (p = 6.3 × 10(-5)). Meta-analysis across all case-control cohorts resulted in p = 4.3 × 10(-8): the rs3778150-C allele (frequency = 16%-19%) being associated with increased heroin addiction risk. Importantly, the functional SNP allele rs1799971-A was associated with heroin addiction only in the presence of rs3778150-C (p = 1.48 × 10(-6) for rs1799971-A/rs3778150-C and p = .79 for rs1799971-A/rs3778150-T haplotypes). Lastly, replication was observed for six other intron 1 SNPs that had prior suggestive associations with heroin addiction (smallest p = 2.7 × 10(-8) for rs3823010). CONCLUSIONS: Our findings show that common OPRM1 intron 1 SNPs have replicable associations with heroin addiction. The haplotype structure of rs3778150 and nearby SNPs may underlie the inconsistent associations between rs1799971 and heroin addiction.
Authors: C Bond; K S LaForge; M Tian; D Melia; S Zhang; L Borg; J Gong; J Schluger; J A Strong; S M Leal; J A Tischfield; M J Kreek; L Yu Journal: Proc Natl Acad Sci U S A Date: 1998-08-04 Impact factor: 11.205
Authors: Thomas Kroslak; K Steven Laforge; Robert J Gianotti; Ann Ho; David A Nielsen; Mary Jeanne Kreek Journal: J Neurochem Date: 2007-10 Impact factor: 5.372
Authors: Jose Manuel Rodriguez; Paolo Maietta; Iakes Ezkurdia; Alessandro Pietrelli; Jan-Jaap Wesselink; Gonzalo Lopez; Alfonso Valencia; Michael L Tress Journal: Nucleic Acids Res Date: 2012-11-17 Impact factor: 16.971
Authors: E R Gamazon; J A Badner; L Cheng; C Zhang; D Zhang; N J Cox; E S Gershon; J R Kelsoe; T A Greenwood; C M Nievergelt; C Chen; R McKinney; P D Shilling; N J Schork; E N Smith; C S Bloss; J I Nurnberger; H J Edenberg; T Foroud; D L Koller; W A Scheftner; W Coryell; J Rice; W B Lawson; E A Nwulia; M Hipolito; W Byerley; F J McMahon; T G Schulze; W H Berrettini; J B Potash; P P Zandi; P B Mahon; M G McInnis; S Zöllner; P Zhang; D W Craig; S Szelinger; T B Barrett; C Liu Journal: Mol Psychiatry Date: 2012-01-03 Impact factor: 15.992
Authors: Frank P Diekstra; Christiaan G J Saris; Wouter van Rheenen; Lude Franke; Ritsert C Jansen; Michael A van Es; Paul W J van Vught; Hylke M Blauw; Ewout J N Groen; Steve Horvath; Karol Estrada; Fernando Rivadeneira; Albert Hofman; Andre G Uitterlinden; Wim Robberecht; Peter M Andersen; Judith Melki; Vincent Meininger; Orla Hardiman; John E Landers; Robert H Brown; Aleksey Shatunov; Christopher E Shaw; P Nigel Leigh; Ammar Al-Chalabi; Roel A Ophoff; Leonard H van den Berg; Jan H Veldink Journal: PLoS One Date: 2012-04-11 Impact factor: 3.240
Authors: Barbara E Stranger; Stephen B Montgomery; Antigone S Dimas; Leopold Parts; Oliver Stegle; Catherine E Ingle; Magda Sekowska; George Davey Smith; David Evans; Maria Gutierrez-Arcelus; Alkes Price; Towfique Raj; James Nisbett; Alexandra C Nica; Claude Beazley; Richard Durbin; Panos Deloukas; Emmanouil T Dermitzakis Journal: PLoS Genet Date: 2012-04-19 Impact factor: 5.917
Authors: Jacqueline M Otto; Ian R Gizer; Joseph D Deak; Kimberly A Fleming; Bruce D Bartholow Journal: Alcohol Clin Exp Res Date: 2017-04-10 Impact factor: 3.455
Authors: Tae-Hwi Schwantes-An; Juan Zhang; Li-Shiun Chen; Sarah M Hartz; Robert C Culverhouse; Xiangning Chen; Hilary Coon; Josef Frank; Helen M Kamens; Bettina Konte; Leena Kovanen; Antti Latvala; Lisa N Legrand; Brion S Maher; Whitney E Melroy; Elliot C Nelson; Mark W Reid; Jason D Robinson; Pei-Hong Shen; Bao-Zhu Yang; Judy A Andrews; Paul Aveyard; Olga Beltcheva; Sandra A Brown; Dale S Cannon; Sven Cichon; Robin P Corley; Norbert Dahmen; Louisa Degenhardt; Tatiana Foroud; Wolfgang Gaebel; Ina Giegling; Stephen J Glatt; Richard A Grucza; Jill Hardin; Annette M Hartmann; Andrew C Heath; Stefan Herms; Colin A Hodgkinson; Per Hoffmann; Hyman Hops; David Huizinga; Marcus Ising; Eric O Johnson; Elaine Johnstone; Radka P Kaneva; Kenneth S Kendler; Falk Kiefer; Henry R Kranzler; Ken S Krauter; Orna Levran; Susanne Lucae; Michael T Lynskey; Wolfgang Maier; Karl Mann; Nicholas G Martin; Manuel Mattheisen; Grant W Montgomery; Bertram Müller-Myhsok; Michael F Murphy; Michael C Neale; Momchil A Nikolov; Denise Nishita; Markus M Nöthen; John Nurnberger; Timo Partonen; Michele L Pergadia; Maureen Reynolds; Monika Ridinger; Richard J Rose; Noora Rouvinen-Lagerström; Norbert Scherbaum; Christine Schmäl; Michael Soyka; Michael C Stallings; Michael Steffens; Jens Treutlein; Ming Tsuang; Tamara L Wall; Norbert Wodarz; Vadim Yuferov; Peter Zill; Andrew W Bergen; Jingchun Chen; Paul M Cinciripini; Howard J Edenberg; Marissa A Ehringer; Robert E Ferrell; Joel Gelernter; David Goldman; John K Hewitt; Christian J Hopfer; William G Iacono; Jaakko Kaprio; Mary Jeanne Kreek; Ivo M Kremensky; Pamela A F Madden; Matt McGue; Marcus R Munafò; Robert A Philibert; Marcella Rietschel; Alec Roy; Dan Rujescu; Sirkku T Saarikoski; Gary E Swan; Alexandre A Todorov; Michael M Vanyukov; Robert B Weiss; Laura J Bierut; Nancy L Saccone Journal: Behav Genet Date: 2015-09-21 Impact factor: 2.805
Authors: John Strang; Nora D Volkow; Louisa Degenhardt; Matthew Hickman; Kimberly Johnson; George F Koob; Brandon D L Marshall; Mark Tyndall; Sharon L Walsh Journal: Nat Rev Dis Primers Date: 2020-01-09 Impact factor: 52.329
Authors: Ji Soo Lee; Jill L Sorcher; Allison D Rosen; Ruslan Damadzic; Hui Sun; Melanie Schwandt; Markus Heilig; John Kelly; Kelsey L Mauro; Audrey Luo; Daniel Rosoff; Christine Muench; Jeesun Jung; Zachary A Kaminsky; Falk W Lohoff Journal: Alcohol Clin Exp Res Date: 2018-05-09 Impact factor: 3.455
Authors: D B Hancock; J L Levy; N C Gaddis; C Glasheen; N L Saccone; G P Page; L J Bierut; A H Kral; E O Johnson Journal: Genes Brain Behav Date: 2015-10-20 Impact factor: 3.449